Over the last few years, major pharmaceutical and biotechnology companies are associating their therapeutic drugs with diagnostic assays to monitor the drug response. This, in turn, enables the pharma companies to facilitate specific drugs for patients with cancer, genetic, and infectious diseases. Cell-free DNA isolation and extraction is one such recently developed method and is gaining immense popularity in the healthcare sector, rapidly. According to the latest market intelligence report by BIS Research titled, ‘Global Cell-Free DNA Isolation and Extraction Market-Analysis and Forecasts (2018-2026),’ the market is anticipated to grow over $442.8 million by the year 2026. This significant market growth is owing to the rising demands for prenatal testing among high-risk pregnant women and increase in demands for liquid biopsy.